Amylyx Pharmaceuticals Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michael DiFiore - Evercore ISI - Analyst : Hi guys, thanks so much for taking my questions and congrats on all the progress. Two for me, one on the PBH Phase 3. Why limit the entry criteria to just Roux-en-Y gastric bypass procedures and not include sleeve gastrectomy, especially when considering the greater prevalence of sleep procedures? And my follow-up is on the PSP ORION study. Could you remind us how efficacy will be interpreted. In this study across regions, given the use of

Question: Michael DiFiore - Evercore ISI - Analyst : Got it thank you.

Question: Joel Beatty - Baird - Analyst : Hi, thanks for taking my questions. For the Wolfram syndrome trial, could you discuss what you're looking for in the week 48 data that will help inform regulatory interactions? And then for a Avexitide, can you discuss the potential to develop that agent for other indications beyond PBH? Thank you.

Question: Madhu Yennawar - Leerink Partners - Analyst : Hi, thanks. This is Madhu on the line from Marc. We've heard from some physicians that there are some patients who exhibit PBH without the postprandial hyperinsulinism. So we're curious if you're screening for patients who specifically show a spike in insulin levels post-meal. Have your research shown, like a specific proportion of patients who show this in PBH? And then also, how should we be thinking of pricing for a avexitide? We know it's early but just wanted to get like a ballpark idea. Thanks.

Question: Madhu Yennawar - Leerink Partners - Analyst : Thanks.